MLICM
RYTM icon

Metropolitan Life Insurance Company (MetLife)’s Rhythm Pharmaceuticals RYTM Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,812
Closed -$122K – 1719
2024
Q1 		$122K Sell
2,812
-156
-5% -$6.83K 0.01% 951
2023
Q4 		$136K Hold
2,968
– – 0.01% 922
2023
Q3 		$68K Buy
2,968
+157
+6% +$3.52K ﹤0.01% 1224
2023
Q2 		$46.4K Buy
+2,811
New +$50.7K ﹤0.01% 1465
2022
Q2 		– Sell
-3,036
Closed -$35K – 2424
2022
Q1 		$35K Sell
3,036
-4,498
-60% -$39.5K ﹤0.01% 1797
2021
Q4 		$75.2K Sell
7,534
-1,259
-14% -$14.1K ﹤0.01% 2612
2021
Q3 		$115K Sell
8,793
-3,657
-29% -$55.8K ﹤0.01% 2446
2021
Q2 		$244K Buy
12,450
+2,835
+29% +$58.9K ﹤0.01% 2002
2021
Q1 		$205K Sell
9,615
-487
-5% -$14.1K ﹤0.01% 2006
2020
Q4 		$300K Hold
10,102
– – ﹤0.01% 1678
2020
Q3 		$219K Hold
10,102
– – ﹤0.01% 1710
2020
Q2 		$225K Hold
10,102
– – ﹤0.01% 1718
2020
Q1 		$154K Buy
10,102
+665
+7% +$11.9K ﹤0.01% 1755
2019
Q4 		$217K Buy
9,437
+1,293
+16% +$28.7K ﹤0.01% 1864
2019
Q3 		$176K Buy
8,144
+2,953
+57% +$63.4K ﹤0.01% 1962
2019
Q2 		$114K Buy
5,191
+689
+15% +$17.4K ﹤0.01% 2229
2019
Q1 		$123K Sell
4,502
-518
-10% -$14.9K ﹤0.01% 2197
2018
Q4 		$135K Buy
5,020
+647
+15% +$17.9K ﹤0.01% 2081
2018
Q3 		$128K Buy
+4,373
New +$138K ﹤0.01% 2304
2018
Q1 		– Sell
-6,757
Closed -$196K – 2492
2017
Q4 		$196K Buy
+6,757
New +$179K ﹤0.01% 1922

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s RYTM Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2024, closing a stake of 2,812 shares — an estimated $122K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in RYTM in Q4 2017 and held it in 20 quarters. The position peaked at $300K in Q4 2020. 165 funds tracked by Wall St. Rank hold RYTM as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Rhythm Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 2,812 Rhythm Pharmaceuticals shares in Q2 2024, an estimated $122K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Rhythm Pharmaceuticals in Q4 2017 and held it in 20 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Rhythm Pharmaceuticals position peaked at $300K in Q4 2020.
  • 165 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.